Jacob Wilson

A Tech and Biotech Investor | Scientist | Own opinions

[Jacob Wilson @jacobw110]

@MeghUpdates India wants AI to help write government tenders. The useful question isn't whether that sounds futuristic. It's whether procurement gets faster without getting dumber. https://t.co/IWVFHIVfNc

#IndianAI #IndiaAI #MeitY #GovTech #AIPolicy

[Jacob Wilson @jacobw110]

China’s new Order 818 path for cell and gene therapy is real. The catch: hospital translation, NMPA approval, and globally portable proof are not the same thing. Here’s the filter to use: https://t.co/uu6O5YDzC2 #ChinaBiotech #CellTherapy #Biotech

[Jacob Wilson @jacobw110]

GSK's bepirovirsen data are real, but the useful question is not just whether 19% looks big. It is which hepatitis B patients qualified, what functional cure actually means, and whether this can scale in high-burden markets.

https://t.co/gp6zvgpIVo

#HepatitisB #GlobalHealth

[Jacob Wilson @jacobw110]

Google is ending consumer Gemini CLI request serving on June 18. I broke down the migration risks that actually matter: plugins, skills, MCP config, auth, and whether your real workflow survives the move. https://t.co/mHIWw9S16g

#AntigravityCLI #GeminiCLI #GoogleAI

[Jacob Wilson @jacobw110]

Akeso's ivonescimab win at ASCO is real. But HARMONi-6 is also a lesson in reading China-to-global biotech evidence: mechanism, comparator, geography, follow-up.

https://t.co/QrixJiE2sh

#Biotech #ChinaBiotech #ASCO2026 #Oncology #LungCancer

[Jacob Wilson @jacobw110]

India's AI GPU portal is live, but it is not free GPUs for everyone. I break down who qualifies, how pricing/subsidy works, and the approval catch builders should know. https://t.co/k5XuIIOI8l #IndiaAI #AIInfrastructure #IndianAI

[Jacob Wilson @jacobw110]

@hqmank Codex got to done. Claude got it to 95%. Alternating then to review each other is helpful.

[Jacob Wilson @jacobw110]

@ritu_twts Claude design is much better in my testing.

[Jacob Wilson @jacobw110]

@Lovable Do we even need lovable after this release?

/goal and /effort set to ultra build
with end goal minimal prompting

https://t.co/w3GrtC5KcA #Claude #AI #ClaudeCode

[Jacob Wilson @jacobw110]

@adocomplete Try opus 4.8 with /goal and /effort set to ultra effort - single prompt to describe end goal and see the magic.
https://t.co/w3GrtC5KcA #Claude #AI #ClaudeCode

[Jacob Wilson @jacobw110]

@kenbwork Try opus 4.8 with /goal and /effort set to ultra effort - single prompt to describe end goal and see the magic.

[Jacob Wilson @jacobw110]

@kenbwork The useful part is the workflow shift: effort control, curated long context, cleaner tool loops, mid-task system messages, and dynamic workflows in Claude Code. https://t.co/w3GrtC5KcA

[Jacob Wilson @jacobw110]

@AnandButani https://t.co/w3GrtC5KcA

[Jacob Wilson @jacobw110]

Claude Opus 4.8 is not just “better Claude.” The useful part is the workflow shift: effort control, curated long context, cleaner tool loops, mid-task system messages, and dynamic workflows in Claude Code. https://t.co/w3GrtC5KcA #Claude #AI #ClaudeCode

[Jacob Wilson @jacobw110]

Caveats still matter. This is what I am covering here. https://t.co/DOydWfnVCu @angelicapeebles

[Barb Loe, NVIC @NVICLoeDown]

China’s Biotech Boom Reshapes Pharma, Sparks U.S. Industry Concerns

Merck announced two licensing deals with Chinese companies, and that really got people’s attention. So what’s going on?

WATCH TVR Best in Video ▶ https://t.co/lEk0phquhh
#ChinaBiotech #Merck #Pharma

[Jacob Wilson @jacobw110]

ADC win is really a China biotech story: Kelun built sac-TMT, Merck is scaling it, and the caveats still matter.

https://t.co/DOydWfnVCu

#Biotech #ChinaBiotech #ADC #Oncology #ASCO2026
$MRK $

[Jacob Wilson @jacobw110]

$DYN filed for accelerated approval in exon 51 Duchenne, but the real story is the evidence bar: surrogate dystrophin, FORZETTO, and what FDA still has to decide. https://t.co/AlB9W8B70O #Biotech #Duchenne #DMD #RareDisease #FDA

[Jacob Wilson @jacobw110]

@bs2537 Published: Replimune's FDA Rejection

FDA rejected Replimune's RP1 again. The Boston biotech lesson is not just the setback. It is how single-arm oncology evidence can become a company-level risk. https://t.co/MXb70Tn5fJ

[Jacob Wilson @jacobw110]

FDA rejected Replimune's RP1 again. The Boston biotech lesson is not just the setback. It is how single-arm oncology evidence can become a company-level risk. https://t.co/MXb70Tn5fJ #Biotech #BostonBiotech #FDA #Oncology #ClinicalTrials

https://t.co/MXb70Tn5fJ

[Jacob Wilson @jacobw110]

@manuelacasasoli It’s promising how the developments are progressing rapidly.

https://t.co/8ToTNnxYUB